<DOC>
	<DOC>NCT02140944</DOC>
	<brief_summary>IMPAACT P1107 will describe the outcomes of HIV-infected persons, ages 12 months and older, who undergo transplantation with CCR5Δ32 cord blood stem cells for treatment of cancer, hematopoietic disease, or other underlying disease.</brief_summary>
	<brief_title>IMPAACT P1107: Effects of Cord Blood Transplantation With CCR5Δ32 Donor Cells on HIV Persistence</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Confirmed HIV1 infection 12 months of age or older Willing to provide written informed consent PreTransplant Cohort: Underlying disease appropriate for stem cell transplant, as determined by the transplant team as part of standard of care. PreTransplant Cohort: Availability of an appropriately matched (as determined by the transplant center) CCR5Δ32 cord blood unit (homozygous or heterozygous) and intention to proceed with transplantation. NOTE: Double cord transplants are allowed. If a double cord is used, at least one cord blood unit should be CCR5∆32 (homozygous or heterozygous). PreTransplant Cohort: Received a CCR5Δ32 homozygous cord blood or bone marrow transplant within the last two years. • Received, or planning to receive, more than one CCR5Δ32 homozygous cord blood or bone marrow transplant.</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Cord blood transplantation</keyword>
	<keyword>CCR5Δ32</keyword>
	<keyword>HIV cure</keyword>
</DOC>